圣湘生物某股东股份拟被司法冻结 上市即巅峰超募13亿

Core Viewpoint - Shengxiang Biotechnology (688289.SH) announced on December 5 that part of the shares held by its major shareholder, Chen Weny, are subject to judicial freezing and enforcement, which will not affect the company's control or daily operations [1][2]. Group 1: Shareholder and Judicial Actions - The shares subject to judicial freezing include 20,720,000 shares, representing 3.58% of the total share capital, which will be adjusted to a "non-restricted sell freeze" status [2]. - The court will allow the applicant to sell up to 4 million shares through the secondary market at a price not lower than 90% of the average price over the previous 30 trading days, with a deadline for the reduction by June 20, 2026 [2]. Group 2: Company Financials and Stock Performance - Shengxiang Biotechnology raised a total of 201.92 million yuan, with a net amount of 186.93 million yuan, exceeding the original plan by 131.27 million yuan [3]. - The company was listed on the Sci-Tech Innovation Board on August 28, 2020, with an initial issuance of 40 million shares at a price of 50.48 yuan per share, and the stock reached a peak of 155.55 yuan on its first trading day [2]. - Currently, the stock is in a state of decline, having fallen below its initial offering price [2].